Prestige Consumer Healthcare Inc (PBH) Expected to Post Quarterly Sales of $252.05 Million

Brokerages expect that Prestige Consumer Healthcare Inc (NYSE:PBH) will report sales of $252.05 million for the current quarter, according to Zacks. Four analysts have provided estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $250.70 million and the highest estimate coming in at $254.80 million. Prestige Consumer Healthcare posted sales of $270.62 million in the same quarter last year, which suggests a negative year-over-year growth rate of 6.9%. The business is expected to report its next earnings report on Thursday, February 7th.

According to Zacks, analysts expect that Prestige Consumer Healthcare will report full-year sales of $988.98 million for the current year, with estimates ranging from $985.00 million to $991.60 million. For the next financial year, analysts forecast that the business will post sales of $983.53 million, with estimates ranging from $980.20 million to $987.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. Prestige Consumer Healthcare had a return on equity of 11.82% and a net margin of 33.38%. The company had revenue of $239.36 million during the quarter, compared to analyst estimates of $236.28 million. During the same quarter last year, the firm posted $0.61 earnings per share. The firm’s revenue was down 7.2% on a year-over-year basis.

PBH has been the subject of a number of research analyst reports. ValuEngine raised Prestige Consumer Healthcare from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 11th. DA Davidson raised their price target on Prestige Consumer Healthcare to $38.00 and gave the stock a “neutral” rating in a research note on Monday, November 5th. Finally, Zacks Investment Research reaffirmed a “hold” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, November 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. Prestige Consumer Healthcare presently has an average rating of “Hold” and an average target price of $39.67.

In other Prestige Consumer Healthcare news, EVP Timothy Connors sold 34,000 shares of the firm’s stock in a transaction on Monday, November 19th. The stock was sold at an average price of $38.25, for a total transaction of $1,300,500.00. Following the completion of the transaction, the executive vice president now owns 25,775 shares of the company’s stock, valued at $985,893.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.14% of the company’s stock.

A number of institutional investors have recently made changes to their positions in PBH. Bank of Montreal Can increased its holdings in shares of Prestige Consumer Healthcare by 135.9% during the second quarter. Bank of Montreal Can now owns 3,067 shares of the company’s stock valued at $118,000 after acquiring an additional 1,767 shares in the last quarter. Zions Bancorporation bought a new position in shares of Prestige Consumer Healthcare during the second quarter valued at $137,000. Tower Research Capital LLC TRC increased its holdings in shares of Prestige Consumer Healthcare by 338.0% during the third quarter. Tower Research Capital LLC TRC now owns 3,754 shares of the company’s stock valued at $142,000 after acquiring an additional 2,897 shares in the last quarter. Rehmann Capital Advisory Group increased its holdings in shares of Prestige Consumer Healthcare by 4,166.4% during the third quarter. Rehmann Capital Advisory Group now owns 5,077 shares of the company’s stock valued at $134,000 after acquiring an additional 4,958 shares in the last quarter. Finally, BlueMountain Capital Management LLC bought a new position in shares of Prestige Consumer Healthcare during the second quarter valued at $208,000.

PBH stock traded down $0.20 on Wednesday, reaching $31.30. The company’s stock had a trading volume of 26,016 shares, compared to its average volume of 378,790. Prestige Consumer Healthcare has a 12-month low of $27.84 and a 12-month high of $46.44. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 1.54 and a beta of 1.01. The company has a quick ratio of 1.38, a current ratio of 2.15 and a debt-to-equity ratio of 1.59.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

Featured Story: What is a stock split?

Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply